Hana Safah, MD

Articles by Hana Safah, MD

Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma

BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD

December 22nd 2022

Hana Safah, MD, explains the common treatment approaches for patients with transplant-ineligible multiple myeloma.

Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma

BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD

December 22nd 2022

Sagar Lonial, MD, introduces the expert panel and starts a conversation on data updates in the treatment of transplant-eligible multiple myeloma.

Trending on OncLive

FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer

FDA Grants Breakthrough Therapy Designation to Telisotuzumab Adizutecan Plus Bevacizumab in Refractory mCRC

FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC

Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC

Etentamig, Iberdomide, and Long-Term PERSEUS Data Headline Key Myeloma Findings From IMS 2026